导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -18.65% | 4281/4773 |
| 近一周 | -6.67% | 5392/5462 |
| 近一月 | -6.01% | 3413/5421 |
| 近一季 | -3.95% | 1506/5209 |
| 近半年 | -21.60% | 4463/4920 |
| 近一年 | -22.68% | 3991/4366 |
| 近两年 | 37.46% | 2000/2954 |
| 近三年 | 6.50% | 1811/2253 |
| 成立以来 | -6.11% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.11% 2681/4961 |
-15.94% 4709/5312 |
- - |
- - |
| 2025 | 27.36% 1563/4813 |
5.53% 765/3635 |
4.97% 671/4076 |
22.05% 1704/4524 |
-5.80% 3621/4813 |
| 2024 | 6.67% 1736/3463 |
2.05% 825/2808 |
-16.55% 2737/3014 |
20.31% 732/3129 |
4.11% 735/3463 |
| 2023 | 20.26% 21/2656 |
38.70% 34/2280 |
6.09% 48/2385 |
-13.24% 2142/2515 |
-5.80% 1504/2655 |
| 2022 | -27.50% 1484/2207 |
-20.90% 1590/1919 |
-2.74% 1789/2016 |
-16.65% 1485/2113 |
13.07% 110/2208 |
| 2021 | 0.95% 699/1822 |
-8.27% 1079/1255 |
2.07% 1015/1330 |
-11.47% 1269/1466 |
21.79% 19/1822 |
| 2020 | 6.55% 872/1250 |
-4.97% 392/1028 |
20.79% 259/1067 |
1.99% 1014/1164 |
-8.99% 1160/1184 |
| 2019 | 27.85% 531/1092 |
31.85% 187/754 |
-16.54% 787/804 |
4.39% 203/850 |
11.30% 67/918 |
| 2018 | -33.55% 555/834 |
- - |
- - |
- - |
-7.48% 65/691 |
| 2017 | -19.24% 576/714 |
- - |
- - |
- - |
- - |
| 2016 | -30.89% 506/605 |
- - |
- - |
- - |
- - |
| 2015 | 56.32% 11/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华中证传媒指数(LOF)A VS. 长安沪深300非周期A(740101) |